{"id":4588,"date":"2026-05-10T17:08:27","date_gmt":"2026-05-10T21:08:27","guid":{"rendered":"https:\/\/mivado.com\/mgp\/?p=4588"},"modified":"2026-05-10T23:24:30","modified_gmt":"2026-05-11T03:24:30","slug":"maximize-compliance-with-ai-assisted-products","status":"publish","type":"post","link":"https:\/\/mivado.com\/mgp\/maximize-compliance-with-ai-assisted-products\/","title":{"rendered":"How to Maximize Compliance in 2026 with AI-Assisted Products?"},"content":{"rendered":"

[vc_row][vc_column][vc_column_text css=””]<\/p>\n

How to Maximize Compliance in 2026 with AI-Assisted Products: Low-Code Product Quality Review (PQR) Application<\/h3>\n

For GMP regulators like Health Canada, the FDA, and the EMA, the Annual Product Quality Review (APQR)<\/a> or Product Quality Review (PQR) in EU\/PIC\/S terms is a critical window into the “health” of a manufacturing process. Regulators view the APQR as a mandatory self-assessment tool (per 21 CFR 211.180(e)<\/a> and EU GMP Chapter 1<\/a>) that ensures a manufacturer is not just producing batches, but actively maintaining a state of control. For decades, the Annual Product Quality Review (APQR) has been the “Mount Everest” of pharmaceutical compliance. As a cGMP expert, I\u2019ve seen the toll it takes: months of manual data extraction from disparate Excel Spreadsheets,\u00a0 ERP, LIMS, and MES systems. They were followed by the grueling task of identifying trends across hundreds of batches. But the landscape has shifted. In 2026, the regulatory expectation isn’t just about having the data. It’s about the speed and depth of your insights. This is why the AI-Assisted\u00a0 APQR Application is no longer a luxury; it is the new standard for manufacturing excellence.[\/vc_column_text][vc_column_text css=””]<\/p>\n

The APQR Crisis: Data-Rich, Information-Poor<\/h2>\n

The traditional APQR process is inherently reactive. By the time a Quality Manager identifies a drifting trend in Cpk (Process Capability Index) or a recurring deviation, months of production have already passed. According to Health Canada’s GUI-0001, FDA 21 CFR 211.180(e), and EU GMP Chapter 1, we are required to evaluate the consistency of our processes. Yet, when done manually, this “evaluation” often becomes a box-ticking exercise rather than a strategic quality tool.[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text css=””]<\/p>\n

The Power of Low-Code + AI<\/h2>\n

The beauty of a Low-Code approach is agility. Quality teams no longer need to wait for a 12-month IT roadmap<\/a> to build a custom reporting tool. With visual, drag-and-drop interfaces, we can build validated workflows that mirror our specific SOPs in weeks, not years. When you infuse this with Artificial Intelligence, the magic happens:<\/p>\n